149 related articles for article (PubMed ID: 34031786)
1. Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib.
Lin JC; Liu CL; Chang YC; Cheng SP; Huang WC; Lin CH; Wu CY; Chen MJ
Invest New Drugs; 2021 Dec; 39(6):1493-1506. PubMed ID: 34031786
[TBL] [Abstract][Full Text] [Related]
2. Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status.
Chang YC; Chen CK; Chen MJ; Lin JC; Lin CH; Huang WC; Cheng SP; Chen SN; Liu CL
Ann Surg Oncol; 2017 Dec; 24(13):4033-4041. PubMed ID: 28744792
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 3β-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer.
Chang YC; Lin CH; Lin JC; Cheng SP; Chen SN; Liu CL
J Surg Res; 2019 Sep; 241():8-14. PubMed ID: 31004874
[TBL] [Abstract][Full Text] [Related]
4. Gossypol enantiomers potently inhibit human placental 3β-hydroxysteroid dehydrogenase 1 and aromatase activities.
Dong Y; Mao B; Li L; Guan H; Su Y; Li X; Lian Q; Huang P; Ge RS
Fitoterapia; 2016 Mar; 109():132-7. PubMed ID: 26709042
[TBL] [Abstract][Full Text] [Related]
5. Chemicals of environmental concern as inhibitors of human placental 3β-hydroxysteroid dehydrogenase 1 and aromatase: Screening and docking analysis.
Tang L; Shi L; Tang Y; Ying Y; Dong Y; Li H; Ge RS
Chem Biol Interact; 2022 Dec; 368():110243. PubMed ID: 36374910
[TBL] [Abstract][Full Text] [Related]
6. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
7. Effects of Methoxychlor and Its Metabolite Hydroxychlor on Human Placental 3β-Hydroxysteroid Dehydrogenase 1 and Aromatase in JEG-3 Cells.
Liu S; Mao B; Bai Y; Liu J; Li H; Li X; Lian Q; Ge RS
Pharmacology; 2016; 97(3-4):126-33. PubMed ID: 26735933
[TBL] [Abstract][Full Text] [Related]
8. Structure/function of the inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 and type 2 by trilostane.
Thomas JL; Mack VL; Glow JA; Moshkelani D; Terrell JR; Bucholtz KM
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):66-73. PubMed ID: 18524572
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of trilostane and cyanoketone on the 3 beta-hydroxysteroid dehydrogenase-isomerase reactions in androgen and 16-androstene biosynthetic pathways in the pig testis.
Cooke GM
J Steroid Biochem Mol Biol; 1996 Apr; 58(1):95-101. PubMed ID: 8809191
[TBL] [Abstract][Full Text] [Related]
10. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Fungicides on Human 3β-Hydroxysteroid Dehydrogenase 1 and Aromatase in Human Placental Cell Line JEG-3.
Cao S; Ye L; Wu Y; Mao B; Chen L; Wang X; Huang P; Su Y; Ge RS
Pharmacology; 2017; 100(3-4):139-147. PubMed ID: 28637041
[TBL] [Abstract][Full Text] [Related]
12. 3 beta-hydroxysteroid dehydrogenase isomerase (3beta-HSD) activity in the rat sciatic nerve: kinetic analysis and regulation by steroids.
Coirini H; Gouézou M; Delespierre B; Schumacher M; Guennoun R
J Steroid Biochem Mol Biol; 2003 May; 85(1):89-94. PubMed ID: 12798361
[TBL] [Abstract][Full Text] [Related]
13. Human placental 3β-hydroxysteroid dehydrogenase/steroid Δ5,4-isomerase 1: Identity, regulation and environmental inhibitors.
Zhu Q; Pan P; Chen X; Wang Y; Zhang S; Mo J; Li X; Ge RS
Toxicology; 2019 Sep; 425():152253. PubMed ID: 31351905
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of phthalates in inhibition of human placental 3β-hydroxysteroid dehydrogenase 1 and aromatase.
Xu RA; Mao B; Li S; Liu J; Li X; Li H; Su Y; Hu G; Lian QQ; Ge RS
Reprod Toxicol; 2016 Jun; 61():151-61. PubMed ID: 27067917
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
16. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.
Jiang C; Xu R; Li XX; Zhou YF; Xu XY; Yang Y; Wang HY; Zheng XFS
Mol Cancer Ther; 2018 Dec; 17(12):2610-2621. PubMed ID: 30224431
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
[TBL] [Abstract][Full Text] [Related]
19. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
